Host-Directed Adjunctive Therapies in Immunocompromised Patients with Pneumonia - 30/01/25
Doi : 10.1016/j.ccm.2024.10.003
Matthew K. Hensley, MD, MPH ⁎ 
, Charles S. Dela Cruz, MD, PhD 1
, Charles S. Dela Cruz, MD, PhD 1 Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
∗Corresponding author. Shadyside Hospital, 5200 Centre Avenue, Suite 610, Pittsburgh, PA 15232.Shadyside Hospital5200 Centre Avenue, Suite 610PittsburghPA15232
Résumé |
Immunocompromised (IC) hosts represent a unique patient population at risk for not only typical pathogens, but also opportunistic microorganisms. While antimicrobials remain the main treatment, new investigations have demonstrated the importance of host-response to pathogens. In this article, we highlight previously discovered and new areas of investigation for adjunctive host-response treatments for IC host pneumonia.
Le texte complet de cet article est disponible en PDF.Keywords: : Immunocompromised, Pneumonia, Host-response, Adjunctive treatment
Plan
© 2024
Elsevier Inc. Tous droits réservés.
Vol 46 - N° 1
P. 37-48 - mars 2025 Retour au numéro
Article précédent
- Vaccines and Other Preventative Strategies for Immunocompromised Pneumonia
- Thomas M. File
- Sequelae of Immunocompromised Host Pneumonia
- Benjamin Salwen, Erica Mascarenhas, David J. Horne, Kristina Crothers, Jerry S. Zifodya
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?